WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2017 The official text of the Prohibited List shall be maintained by WADA and sh

Transcription

1 세계도핑방지규약국제표준 2017 년금지목록국제표준

2 WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2017 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2017

3 세계도핑방지규약국제표준 2017 년금지목록국제표준 이목록은 2017 년 1 월 1 일부터발효된다. 금지목록국제표준은세계도핑방지기구 (WADA) 에의해관리된다. 영문판과불문판이발간되며, 상호상충될경우영문판이우선한다. 주해 : 본책자는영문판과한글판을대비하여게재하였다. 영문판과한글판상호간상충이있을경우영문판이우선한다.

4 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS SPECIFIED SUBSTANCES EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES S0 Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1 ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) a. Exogenous* AAS, including: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); Bolandiol (estr-4-ene-3β,17β-diol ); Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4,5 :2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst-2- en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3,4 :2,3]-5αandrostan-17β-ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4- dien-3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5αandrostan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9- dien-3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5αandrost-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr- 4-en-3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17αmethylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1 Hpyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor- 17α-pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 2

5 상시금지되는약물및방법 ( 경기기간중및경기기간외 ) 세계도핑방지규약제 항에따라, S1, S2, S4.4, S4.5, S6.a 로분류되는약물그리고 M1, M2 및 M3 금지방법이외의모든금지약물은 특정약물 로간주된다. 금지약물 S0 비승인약물 금지목록의어떠한분류에도포함되지않으며, 각국정부산하의 보건기구에서사람의치료를위하여사용하도록현재승인하지않은모든약리적물질 ( 예 : 임상전또는임상개발중또는생산이중단된약물, 합성마약및동물용으로만승인된약물 ) 은항상금지된다. S1 동화작용제 동화작용제는금지된다. 1. 동화작용남성호르몬스테로이드 (AAS) a. 외인성 * 동화작용남성호르몬스테로이드, 다음을포함 ; 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); Bolandiol (estr-4-ene-3β,17β-diol ); Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4,5 :2,3]pregna-4-en-20-yn-17αol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst-2- en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3,4 :2,3]-5αandrostan-17β-ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4- dien-3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5αandrostan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9- dien-3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5αandrost-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr- 4-en-3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17αmethylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1 Hpyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor- 17α-pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); 그리고화학적구조또는생물학적효과가유사한다른약물들. 2

6 b. Endogenous** AAS when administered exogenously: 2. OTHER ANABOLIC AGENTS 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); Nandrolone (19-nortestosterone); Prasterone (dehydroepiandrosterone, DHEA,3βhydroxyandrost-5-en-17-one); Testosterone; Including, but not limited to: Clenbuterol; Selective androgen receptor modulators (SARMs, e.g.andarine and ostarine); Tibolone; Zeranol; Zilpaterol. For purposes of this section: * exogenous refers to a substance which is not ordinarily produced by the body naturally. ** endogenous refers to a substance which is ordinarily produced by the body naturally. and their metabolites and isomers, including but not limited to: 3β-Hydroxy-5α-androstan-17-one; 5α-Androst-2-ene-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β, 17β-diol); 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietin-Receptor agonists: 1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. Darbepoietin (depo); Erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; GATA inhibitors, e.g. K-11706; Methoxy polyethylene glycol-epoetin beta (CERA); Transforming Growth Factor-β (TGF-β) inhibitors, e.g. sotatercept, luspatercept;. 1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290; Asialo EPO; Carbamylated EPO. 2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt, molidustat and roxadustat (FG-4592); and HIF activators, e.g. argon and xenon. 3

7 b. 외인성으로투여된내인성 ** 동화작용남성호르몬스테로이드 : 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); Nandrolone (19-nortestosterone); Prasterone (dehydroepiandrosterone, DHEA,3βhydroxyandrost-5-en-17-one); Testosterone; 2. 기타동화작용제 다음약물들을포함하나이에국한되지않음 : Clenbuterol, 선택적안드로겐수용체변조제 (SARMs, 예. andarine과 ostarine) Tibolone Zeranol Zilpaterol. 본항목에서 : * 외인성 이란자연적으로체내에서생성되지않는약물을말한다. ** 내인성 이란자연적으로체내에서생성되는약물을말한다. 그리고그대사물질및이성질체, 다음을포함하나이에국한되지않음 : 3β-Hydroxy-5α-androstan-17-one; 5α-Androst-2-ene-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β, 17β-diol); 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. S2 펩티드호르몬, 성장인자, 관련약물및유사제 다음의약물과이와화학적구조또는생물학적효과가유사한다른약물들은금지된다 : 1. 에리스로포이에틴수용체작용제 : 1.1 적혈구생성자극제 (ESAs) 다음을포함 ( 예 ) 다베포이에틴 (depo); 에리스로포이에틴 (erythropoietin, EPO); EPO-Fc; EPO-유사펩티드 (EMP), ( 예 ) CNTO530과페기네사타이드 (peginesatide); GATA 억제제류, ( 예 ) K-11706; Methoxy polyethylene glycol-epoetin beta(cera); Transforming Growth Factor-β(TGF-β) 억제제, ( 예 ) sotatercept, luspatercept; 1.2 비조혈성 EPO 수용기작용제, ( 예 ) ARA-290; asialo EPO; carbamylated EPO. 2. 저산소증유도인자 (HIF) 안정제, ( 예 ) cobalt, molidustat 그리고 roxadustat(fg-4592); 그리고 HIF 활성제, ( 예 ) argon, xenon 3

8 3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and leuprorelin, in males. 4. Corticotrophins and their releasing factors, e.g. corticorelin. 5. Growth Hormone (GH) and its releasing factors including: Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2). Additional prohibited growth factors: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity, or fibre type switching. S3 BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Vilanterol. Except: Inhaled salbutamol (maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours; Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; Inhaled salmeterol: maximum 200 micrograms over 24 hours The presence in urine of salbutamol in excess of 1000 ng/ml or formoterol in excess of 40 ng/ml is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding [AAF]unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic dose (by inhalation) up to the maximum dose indicated above. HORMONE AND METABOLIC S4 MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomiphene; Cyclofenil; Fulvestrant. 4

9 3. 융모성고나도트로핀 (CG) 과황체 ( 黃體 ) 형성호르몬 (LH) 그리고관련방출인자, 예. buserelin, gonadorelin 및 leuprorelin, 남성만금지. 4. 부신피질자극호르몬 (Corticotrophins) 과관련방출인자, ( 예 ) corticorelin. 5. 성장호르몬 (Growth Hormone: GH) 과관련방출인자, 다음을포함한다 : 성장호르몬방출호르몬 (GHRH) 와그유사제, ( 예 ) CJC-1295, sermorelin 그리고 tesamorelin; 성장호르몬분비촉진제 (GHS), ( 예 ) ghrelin, ghrelin 유사제, ( 예 ) anamorelin, ipamorelin; 성장호르몬분비펩티드 (GHRPs), ( 예 ) alexamorelin, GHRP-6, hexarelin과pralmorelin(ghrp-2). 예외 : 흡입에의한 salbutamol : 12시간당 800마이크로그램을초과하지않는 24시간동안최대 1600마이크로그램 흡입에의한 formoterol : 24시간동안최대 54마이크로그램의전달량 흡입에의한 salmeterol : 24시간동안최대 200마이크로그램소변시료 1ml당 1,000ng을초과하는 salbutamol 또는 1ml 당 40ng을초과하는 formoterol 검출시치료목적의도가아닌것으로간주되며, 만약에선수가통제된약물동태학적조사를통하여비정상적인결과가위명시된치료목적흡입량을최대로사용한바에기인한것임을입증하지못하는경우비정상분석결과 (AAF) 로간주된다. 또한, 다음의성장인자들은금지된다. 섬유아세포성장인자 (FGFs); 간세포성장인자 (HGF); 유사인슐린성장인자-1 (IGF-1) 과그유사제 ; 메카노성장인자 (MGFs); 혈소판유도성장인자 (PDGF) 혈관내피계성장인자 (VEGF) 그리고근육, 건 ( 腱 ) 또는인대단백질합성 / 분해, 혈관신생, 에너지효율, 재생력또는섬유질형태전환에영향을미치는기타모든성장인자. S3 베타 -2 작용제 광학이성질체를포함한모든선택적이며비선택적베타-2 작용제는금지된다 ; 다음을포함하며이에국한되지않음 : Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Vilanterol. S4 호르몬및대사변조제 다음의호르몬과대사조절인자들은금지된다 : 1. 아로마테이즈억제류 (Aromatase inhibitors), 다음약물을포함하나이에국한되지않음 : 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. 선택적에스트로겐수용체변조물질류 (Selective estrogen receptor modulators : SERMs), 다음약물을포함하나이에국한되지않음 : Raloxifene; Tamoxifen; Toremifene. 3. 기타항에스트로겐류 (Other anti-estrogenic substances), 다음약물을포함하나이에국한되지않음 : Clomiphene; Cyclofenil; Fulvestrant. 4

10 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. PROHIBITED METHODS 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516; 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. S5 DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan. Except: Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide). Local administration of felypressin in dental anaesthesia. The detection in an Athlete s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding [AAF]unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. M1 MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M2 CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases. 2. Intravenous infusions and/or injections of more than 50 ml per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations. M3 GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of polymers of nucleic acids or nucleic acid analogues; 2. The use of normal or genetically modified cells. 5

11 4. myostatin 기능변조제류 (Agents modifying myostatinfunction(s)), 다음약물을포함하나이에국한되지않음 : myostatin 억제제류 상시금지되는방법 5. 대사변조제 5.1 AMP-활성화단백질키나아제활성제 (AMPK), ( 예 ) AICAR; Peroxisome 증식활성화수용체 δ 작용제, 예. GW 1516; 5.2 인슐린과인슐린유사제 5.3 Meldonium; 5.4 Trimetazidine. S5 이뇨제및기타은폐제 다음의이뇨제와은폐제들은금지되며이와화학적구조 또는생물학적효과가유사한기타약물들도금지된다. M1 혈액및혈액성분의조작 다음사항은금지된다. 1. 자가혈액, 동종혈액또는이종혈액및모든출처의적혈구제제를순환계에투여또는재주입. 2. 산소의섭취, 운반또는전달의인위적향상. 다음사항을포함하나이에국한되지않음 : 불소치환화합물 ; efaproxiral (RSR13) 그리고변형헤모글로빈제품류, ( 예 : 헤모글로빈을재료로한혈액대체제, 마이크로캡슐로된헤모글로빈제품 ). 흡입을통한산소보충은제외. 3. 물리적또는화학적수단을이용한혈액또는혈액성분에대한모든형태의혈관내조작. 다음을포함하나이에국한되지않음 : 데스모프레신 (Desmopressin); 프로베네시드 (probenecid), 혈장확장제 (plasma expanders) ( 예 ) 글리세롤 (glycerol), 정맥투여형태의알부민 (albumin), 덱스트란 (dextran), 히드록시에틸전분 (hydroxyethyl starch) 및마니톨 (mannitol) Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, ( 예 ) bendroflumethiazide, chlorothiazide 그리고 hydrochlorothiazide; triamterene와 vaptans, ( 예 ) tolvaptan. 예외 : Drospirenone; pamabrom; 그리고탄산탈수효소억제제 ( 예. dorzolamide, brinzolamide) 의안과적사용. 치과마취를위한 felypressin의국소투여. Formoterol, salbutamol, cathine, ephedrine, methylephedrine및 pseudoephedrine과같이한계치가정해진약물이이뇨제또는은폐제와함께상시또는경기기간중의선수시료에서소량이라도검출될경우, 이뇨제또는은폐제에대한치료목적사용면책 (TUE) 과더불어해당약물에대한승인된치료목적사용면책 (TUE) 을보유하고있지않는한비정상분석결과 (AAF) 로간주된다. M2 화학적, 물리적조작 다음사항은금지된다. 1. 도핑검사과정에서채취된시료의성분과유효성을변조하거나변조를시도하는행위. 다음사항을포함하나이에국한되지않음 : 소변바꿔치기및 / 또는불순물 ( 예 : 단백질분해효소 ) 섞기 2. 6시간동안 50ml보다많은양의정맥투여및 / 또는정맥주사는금지된다. 단, 입원, 수술절차또는임상조사과정에서의료기관에의해합법적으로처치된경우는제외된다. M3 유전자도핑 경기력향상의가능성을가진다음과같은사항은금지된다 : 1. 핵산고분자또는핵산유사물의이동 2. 정상또는유전적으로조작된세포의사용 5

12 SUBSTANCES & METHODS PROHIBITED IN-COMPETITION IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION: PROHIBITED SUBSTANCES S6 STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. b: Specified Stimulants. Including, but not limited to: 4-Methylhexan-2-amine (methylhexaneamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α- pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; A stimulant not expressly listed in this section is a Specified Substance. 6

13 경기기간중금지되는약물및방법 앞서규정된 S0 부터 S5, M1 부터 M3 에추가하여다음분류들이경기기간중에금지된다. 금지약물 S6 흥분제 광학이성질체 ( 예. d- 와 l-) 를포함한모든흥분제류는금지된다. 흥분제종류는다음과같다 : a: 비특정흥분제 : Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. b: 특정흥분제다음사항을포함하나이에국한되지않음 : 4-Methylhexan-2-amine (methylhexaneamine); Benzfetamine; Cathine**; cathinone과그유사제들, ( 예 : mephedrone, methedrone, α-pyrrolidinovalerophenone); Dimethylamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine 과그유도체, Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 이항목에명확히명시되지않은흥분제는특정약물이다. 6

14 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: Clonidine Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2016 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2016 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. S7 NARCOTICS Prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Licomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. S8 CANNABINOIDS Prohibited: Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC). Cannabimimetics, e.g. Spice, JWH-018, JWH-073, HU-210. S9 GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular, or rectal routes. 7

15 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; 그리고이러한약물과화학적구조또는생물학적효과가유사한다른약물들. 예외 : Clonidine 2017 모니터링프로그램 * 에포함된흥분제들과국소적또는안과적치료에사용되는 Imidazole 유도물. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol 과 synephrine : 이약물들은 2017 모니터링프로그램에포함되며금지약물에해당되지않는다. ** Cathine: 그농도가소변에 ml 당 5마이크로그램보다높을경우금지된다. *** Ephedrine과 methylephedrine: 그농도가소변에 ml 당 10마이크로그램보다높을경우금지된다. **** Epinephrine (adrenaline): 국소투약은금지되지않는다. ( 예. 코, 눈또는국소마취제의복합투여 ) ***** Pseudoephedrine: 그농도가소변에 ml 당 150마이크로그램보다높을경우금지된다. S7 마약 금지 : Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl 그리고유도체 ; Hydromorphone; Methadone; Morphine; Licomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. S8 카나비노이드 금지 : 천연 ( 예 : 대마초, 해시시, 마리화나 ) 또는합성델타9-tetrahydrocannabinol (synthetic Δ9-tetrahydrocannabinol:THC) 유사대마초 ( 예 ) Spice, JWH-018, JWH-073, HU-210. S9 글루코코르티코이드 경구복용, 정맥주사, 근육주사또는좌약형태로투여하는모든글루코코르티코이드는금지된다. 7

16 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS ALCOHOL P1 Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/l. Air Sports (FAI) Automobile (FIA) Archery (WA) Powerboating (UIM) BETA-BLOCKERS P2 Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of Competition where indicated. Archery (WA)* Automobile (FIA) Billiards (all disciplines) (WCBS) Darts (WDF) Golf (IGF) Shooting (ISSF, IPC)* Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol; Celiprolol; Esmolol; Labetalol; Levobunolol; Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol; Timolol. 8

17 특정종목에서금지되는약물 P1 알코올 (ALCOHOL) 알코올 (ethanol) 은다음종목에서경기기간중에만금지된다. 검사는호흡및 / 또는혈액분석을통하여시행된다. 도핑위반한계치는혈중알코올농도 0.10 g/l에해당된다. 항공스포츠 ( 국제항공스포츠연맹 : FAI) 양궁 ( 국제양궁연맹 : WA) 자동차경주 ( 국제자동차연맹 : FIA) 모터보트 ( 국제모터보트연맹 : UIM) P2 베타차단제 (BETA-BLOCKERS) 베타차단제류는다음종목에서경기기간중에만금지되며, 표시되어있는경우경기기간외에도금지된다. 양궁 ( 국제양궁연맹 : WA)* 자동차경주 ( 국제자동차연맹 : FIA) 당구 ( 모든세부종목 ) ( 국제당구연맹 : WCBS) 다트 ( 국제다트연맹 : WDF) 골프 ( 국제골프연맹 : IGF) 사격 ( 국제사격연맹 : ISSF, 국제장애인올림픽위원회 : IPC)* 스키 / 스노우보드 ( 국제스키연맹 : FIS) 스키점프, 프리스타일에어리얼 / 하프파이프, 스노우보드하프파이프 / 빅에어 수중 ( 세계수중연맹 : CMAS) 핀착용또는미착용콘스탄트웨이트애프니아, 핀착용또는미착용다이나믹애프니아, 프리이머전애프니아, 점프블루애프니아, 스피어피싱, 스태틱애프니아, 목표물사격과베리어블웨이트애프니아. * 경기기간외에도금지 다음약물을포함하지만이에국한되지않음 : Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol; Celiprolol; Esmolol; Labetalol; Levobunolol; Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol; Timolol. 8

18 THE 2017 MONITORING PROGRAM* The following substances are placed on the 2017 Monitoring Program: The following substances are placed on the 2017 Monitoring Program: 1. Stimulants: 2. Narcotics: 3. Glucocorticoids: 4. Telmisartan: 5. Beta-2-agonists: In-Competition only: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine. In-Competition only: Codeine, mitragynine and tramadol. In-Competition (by routes of administration other than oral, intravenous, intramuscular or rectal) and Out-of-Competition (all routes of administration). In- and Out-of-Competition. In- and Out-of-Competition: any combination of beta-2-agonists. * The World Anti-Doping Code (Article 4.5) states: WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport. 9

19 2017 모니터링프로그램 * 다음약물들은 2017 모니터링프로그램에포함된다. 1. 흥분제류 : 2. 마약류 : 3. 글루코코르티코이드 : 4. Telmisartan : 5. 베타-2 작용제 : 경기기간중에만적용 : Bupropion, caffeine, nicotine phenylephrine, phenylpropanolamine, pipradrol 그리고 synephrine. 경기기간중에만적용 : Codeine, Mitragynine 그리고 tramadol. 경기기간중 ( 경구, 정맥, 근육또는좌약이외의방법으로투여 ), 경기기간외 ( 모든방법의투여 ) 경기기간중및경기기간외 경기기간중과경기기간외 : 베타 -2 작용제의모든복합사용 * 세계도핑방지규약 (WADC) 4.5항 : 세계도핑방지기구는가맹기구및각국정부와협력하여금지목록에없으나스포츠에서약물남용의유형을감지하기위하여세계도핑방지기구가감시하고자하는약물에대한모니터링프로그램을수립한다. 9

20 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2017 PROHIBITED LIST Substances and methods prohibited at all times (In- and Out-of-Competition) Prohibited Substances S1 ANABOLIC AGENTS S3 BETA-2-AGONISTS Compounds boldenone, boldione, 19-norandrostenedione, and nandrolone have been transferred and 19-norandrostenediol added to the S1.b section because they can be produced endogenously at low concentrations. This change does not affect the prohibited status of these substances. The interpretation and reporting of findings for these substances is addressed in specific Technical Documents (TD2016IRMS and/or TD2016NA). 5α-androst-2-ene-17-one, commonly known as Delta-2 or 2-androstenone, was added as an example of metabolite of DHEA, more recently found in dietary supplements.b: Specified Stimulants. S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS To extend the scope of Erythropoietic Stimulating Agents, GATA inhibitors (e.g. K-11706) and Transforming Growth Factor- β (TGF-β) inhibitors (e.g. sotatercept, luspatercept) were added. The reference to isomers was simplified. Examples of selective and non-selective beta-2-agonists were added (fenoterol, formoterol, higenamine, indacaterol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, vilanterol). Higenamine is documented to be a constituent of the plant Tinospora crispa, which can be found in some dietary supplements and is a non-selective beta-2-agonist. Dosing parameters of salbutamol were refined to make it clear that the full 24 hour dose should not be administered at one time. The maximum dosage for salmeterol was stated according to the manufacturers recommendations. Studies are ongoing to establish an appropriate urinary threshold concentration for inhaled salmeterol. At present, the Technical Document TD2015MRPL recommends not to report salmeterol below 10 ng/ml. The International Nonproprietary Name (INN) of FG-4592, roxadustat, was added. S4 HORMONE AND METABOLIC MODULATORS Molidustat was added as another example of HIF stabilizer. Cobalt: It is re-iterated that vitamin B12, which contains cobalt, is not prohibited. Androsta-3,5-diene-7,17-dione (arimistane) was added as a new example of aromatase inhibitor. Prohibited Methods M1 MANIPULATION OF BLOOD AND BLOOD COMPONENTS Supplemental oxygen administered by inhalation, but not intravenously, is permitted. To clarify this, M1.2 now reads excluding supplemental oxygen by inhalation. 10

21 2017 년금지목록국제표준주요변경사항및주해 상시금지되는약물및방법 ( 경기기간중및경기기간외 ) 금지약물 S1 동화작용제 S3 베타 -2- 작용제 화합물 boldenone, boldione, 19-norandrostenedione 그리고 nandrolone이 S1.b 분류로이동되었고 19-norandrostenediol이 S1.b 분류에추가되었으며이는이성분들이낮은농도의내인성으로생성될수있기때문이다. 이변화가이러한물질들의금지상태에영향을미치는것은아니다. 이러한물질검출에대한보고및해석은특정기술문서 (TD2016IRMS 와 / 또는 TD2016NA) 에의해다루어진다. 일반적으로 Delta-2 또는 2-androstenone로알려져있는 5α -androst-2-ene-17-one가최근식이보충제내에서발견되는 DHEA 대사물의예로추가되었다. 이성질체에대한목록을단순화하였다. 선택적이며비선택적베타-2 작용제의예를추가하였다 (fenoterol, formoterol, higenamine, indacaterol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, vilanterol). 일부식이보충제에서발견되고비선택적베타-2 작용제인 Higenamine은 Tinospora crispa 식물의구성성분으로알려져있다. 24시간의총사용량을 1회에투약하지말아야하는것을명확히하기위하여 salbutamol의사용기준을개선하였다. salmeterol의최대사용량은제조사의권고에따라기술하였다. S2 펩티드호르몬, 성장인자, 관련약물및유사제 흡입 salmeterol에대한적절한소변역치농도를확립하기위한연구는계속되고있다. 현재, 기술문서인 TD2015MRPL는 10ng/mL이하의 salmeterol의보고하지않는것을권장한다. 조혈성자극제범위의확장에따라 GATA 억제제류 ( 예. K-11706) 와 Transforming Growth Factor-β(TGF-β) 억제제류 ( 예. sotatercept, luspatercept) 가추가되었다. FG-4592 의국제일반명명칭인 roxadustat 가추가되었다. Molidustat 가 HIF stabilizer 의또다른예로추가되었다. S4 호르몬및대사변조제 코발트 : 코발트를포함하고있는 vitamin B12는금지되지않는다는것을다시반복한다. 아로마테이즈억제제의새로운예시로 Androsta-3,5-diene-7,17-dione(arimistane) 가추가되었다. 금지방법 M1 혈액및혈액성분의조작 흡입형태의산소지원은허가되나정맥내투여는불가하다. 이를분명히하기위해지금 M1.2를확인하면 흡입을통한산소의지원은제외 10

22 Substances and Methods Prohibited In-Competition MONITORING PROGRAM The following were added to establish patterns of use: S6 STIMULANTS Codeine; Concurrent use of multiple beta-2-agonists. Lisdexamfetamine was added to S6.a; it is an inactive pro-drug of amfetamine. In the absence of an INN for methylhexaneamine, its International Union of Pure and Applied Chemistry (IUPAC) name, 4-methylhexan-2-amine, was added. A number of other synonyms exist for methylhexaneamine including: 1,3-dimethylamylamine, dimethylpentylamine; methylhexamine; methylhexanamine; 1,3-dimethylpentylamine. Regular food consumption will not yield sufficient levels of phenylethylamine to result in an Adverse Analytical Finding. S7 NARCOTICS Nicomorphine was added. It is an opioid analgesic drug, which is converted to morphine following administration. S9 GLUCOCORTICOIDS After consideration of stakeholders comments, no changes were made in this section for

23 경기기간중금지약물및금지방법 S6 흥분제 Lisdexamfetamine이 S6.a에추가되었다 ; 이는 amfetamine의비활성 pro-drug이다. 모니터링프로그램 사용형태의변화에따라다음을추가하였다. 코데인 다수의베타-2 작용제의동시적사용 methylhexaneamine의국제일반명부제에따라국제순수 응용화학연합명칭인 4-methylhexan-2-amine를추가하였다. methylhexaneamine의동의어로는 1,3-dimethylamylamine, dimethylpentylamine; methylhexamine; methylhexanamine; 1,3-dimethylpentylamine이있다. 일반적인음식섭취는 AAF의결과를위해충분한 phenylethylamine 수준을만들지못한다. S7 마약 Nicomorphine이추가되었다. 이는투여에따라 morphine으로변화되는아편류진통제이다. S9 글루코코르티코이드 가맹기구의의견을고려후, 2017 년해당분류는변화시키지않았다. 11

24

25 2017 년금지목록국제표준 THE 2017 PROHIBITED LIST INTERNATIONAL STANDARD 2017 년 1 월 1 일 2016 년 12 월발행

26